BIO 300 Shows Promise in Improving Pulmonary Function in Post-COVID-19 Patients
• Humanetics Corporation's BIO 300 demonstrated statistically significant improvement in pulmonary function (FEV1) at 12 weeks, maintained at 12 months in post-COVID-19 patients.
• The Phase 2 trial also showed trends toward improved pulmonary function (DLCO, FVC) and enhanced quality of life in BIO 300-treated participants.
• BIO 300 was well-tolerated, with adverse events consistent with the patient population, and no new safety concerns were identified during the trial.
• Humanetics is further evaluating BIO 300 for COVID-19 and other conditions involving lung inflammation, as well as medical countermeasure and oncology applications.
Humanetics Receives Additional Funding to Advance BIO 300 for Radiation Injury Prevention
• Humanetics Corporation secured an additional $5 million from the Department of Defense to further develop BIO 300, a drug aimed at mitigating harm from acute radiation exposure.
• The funding will support manufacturing enhancements for both the drug substance and product of BIO 300, strengthening domestic production capabilities within the United States.
• Clinical and nonclinical studies of BIO 300 will also be supported, accelerating its development towards FDA approval and potential emergency use authorization.
• BIO 300 is being developed as a medical countermeasure for acute radiation syndrome, addressing a critical need for prophylactic radioprotectants for military, first responders, and civilians.
© Copyright 2025. All Rights Reserved by MedPath